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B
ritain’s House of Commons 
Health Committee has recently 
recommended a fundamental 
realignment of the relationships 
between the pharmaceutical industry 
and government, regulators, doctors, 
the health service, and patients 
[1]. The committee said that the 
industry has interdigitated itself into 
every aspect of health care, and that 
government and others, including 
doctors, have taken the easy route 
of assuming that the interests of the 
industry and of the health services and 
patients are the same. 
The committee’s report makes clear 
that reducing the inﬂ  uence of the 
industry would be good for everybody, 
including—paradoxically—the industry 
itself, which could concentrate on 
developing new drugs rather than 
on corrupting doctors, patient 
organisations, and others. “It is not in 
the long term interests of the industry 
for prescribers and the public to lose 
faith in it,” says the report. “We need 
an industry which is led by the values of 
its scientists not those of its marketing 
force.”
Select Committees: Rationality 
before Realpolitik
The Health Committee is one of 
many select committees of the House 
of Commons. The committees are 
comprised of members of parliament 
and politicians from all parties, and 
they can choose to examine any 
subject that raises matters of public 
importance. They receive written 
and oral evidence, including from 
government ministers, and produce 
reports and recommendations to which 
the government is required to respond. 
The 11-member Health Committee 
chose to examine the inﬂ  uence of the 
drug industry because of increasing 
public concern that this inﬂ  uence 
is excessive. The committee was 
particularly worried by the industry’s 
role in promoting “medicalisation,” the 
idea of a pill for every ill: “What has 
been described as the ‘medicalisation’ 
of society—the belief that every 
problem requires medical treatment—
may also be attributed in part to 
the activities of the pharmaceutical 
industry” [1]. The committee, whose 
terms of reference are shown in 
Box 1, was also worried by the high 
prevalence of drug side effects. It heard 
from every interested party, including 
representatives of the drug companies, 
patients, doctors, medical journal 
editors, critics of the industry, and 
government ministers and ofﬁ  cials.
The government does not have to 
accept the recommendations from 
select committees, and it recently 
rebuffed recommendations from the 
same Health Committee encouraging 
open access to scientiﬁ  c research [2]. 
Usually, the committees will be much 
bolder than the government, which 
is heavily lobbied and pays more 
attention to realpolitik than to rational 
argument. Just as the publishing 
industry pressured the government 
to ignore recommendations on open 
access [3], the pharmaceutical industry 
will be doing the same now—and the 
industry is powerful; it is Britain’s third 
most proﬁ  table economic activity (after 
tourism and ﬁ  nance) and employs 
83,000 people.
The Essay section contains opinion pieces on topics 
of broad interest to a general medical audience. 
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Box 1. Terms of Reference for 
the Health Committee Enquiry
“The Health Committee is to undertake 
an inquiry into the inﬂ  uence of the 
pharmaceutical industry on health 
policies, health outcomes and future 
health priorities and needs. The inquiry 
will focus, in particular, on the impact of 
the industry on the following:
• drug innovation
• the conduct of medical research
• the provision of drug information and 
promotion
• professional and patient education
• regulatory review of drug safety and 
efﬁ  cacy
• product evaluation, including 
assessments of value for money
In doing so, the Committee 
will examine the inﬂ  uence of the 
pharmaceutical industry on the NHS; 
National Institute for Clinical Excellence 
(NICE); regulatory authorities and 
advisory and consultative bodies; 
prescribers, suppliers and providers of 
medicines; professional, academic and 
educational institutions; the (professional 
and lay) press and other media; and 
patients, consumers, the general public 
and representative bodies.”
(Information taken from [1])PLoS Medicine  |  www.plosmedicine.org 0822
The All-Pervasive and Persistent 
Inﬂ  uence of the Industry
Although the pharmaceutical industry 
is now perceived by the public as 
putting proﬁ  ts ahead of patients’ 
well-being [4], it is generally, as the 
committee makes clear, a force for 
good. Almost all of the drugs that have 
transformed medicine in the past half 
century have been developed and 
manufactured by the industry. “The 
discovery, development and effective 
use of drugs,” says the committee, 
“have improved many people’s quality 
of life, reduced the need for surgical 
intervention and the length of time 
spent in hospital and saved many 
lives” [1]. And making the industry 
into a scapegoat for failing to produce 
drugs for the diseases of the poor 
is in some ways no more sensible, I 
believe, than blaming washing machine 
manufacturers for poor hygiene 
standards in the developing world. 
The industry is part of the for-proﬁ  t 
sector, and has what many philosophers 
might call a moral duty to maximise 
proﬁ  ts. Producing drugs for the poor 
requires imaginative public–private 
partnerships. 
It’s also shallow thinking to view the 
industry as corrupters and doctors as 
the corrupted. As a doctor myself, I 
think that doctors are in many ways 
to blame for the debased relationship 
between themselves and the industry. 
The industry is (mostly) behaving 
in ways that are “normal” within the 
commercial sector. It is the doctors who 
depart from their ethical base when 
they insist on ﬁ  rst-class fares and lavish 
entertainment from the industry so 
that they can attend an international 
conference.
The fundamental problem, says the 
committee, is that the pharmaceutical 
industry’s inﬂ  uence is too pervasive: 
“The industry affects every level of 
healthcare provision, from the drugs 
that are initially discovered and 
developed through clinical trials, 
to the promotion of drugs to the 
prescriber and the patient groups, to 
the prescription of medicines and the 
compilation of clinical guidelines.” 
The committee goes into detail 
about each of these levels. Regulatory 
authorities, it says, are too close to 
the industry, meaning that they do 
not ensure that the industry works in 
the public interest. The clinical trials 
that are the essential evidence base 
for regulatory and clinical decisions 
are produced almost entirely by the 
industry, and the evidence that reaches 
authorities, doctors, and patients is 
biased. Guidelines for treating patients 
are distorted, not only because they 
must be based on biased evidence, but 
also because the organisations and 
people producing them are often in 
hock to the industry. The organisations 
may receive millions of British pounds 
for buildings and activities, while the 
individuals—particularly key opinion 
leaders (KOLs, as they are known in 
the trade)—may receive hundreds of 
thousands of pounds for consultancy, 
speaking fees, travel, research, and 
articles. “Drug companies are criticised 
for giving hospitality and recruiting 
‘key opinion leaders’,” says the 
committee, “but the prescribers must 
be equally to blame for accepting the 
hospitality and some ‘key opinion 
leaders’ for lending their names to 
work they did not produce, often for 
very considerable sums.”
Next in the list of things that 
concerned the committee comes 
the industry’s intensive marketing, 
which is becoming ever more 
important as the ﬂ  ow of drugs that 
offer major therapeutic advances 
(and so need much less marketing) 
dries up. Britain has some 8 000 
drug company representatives, but 
the industry also spends millions on 
advertising, sponsorship, meetings, and 
increasingly, “medical education”—
which often means a ﬁ  ne dinner and 
a lecture from a captive KOL. The 
report states: “Coupled with company-
sponsored information from medical 
journals and supplements, ‘medical 
education’ materials, advertisements 
and sponsorship to attend conferences, 
workshops and other events, it is little 
wonder that prescribing practices are 
affected.” Medical journals, as I’ve 
argued in PLoS Medicine [3], are in 
some ways extensions of the marketing 
arm of the industry, while the free 
newspapers that overwhelm doctors in 
the developed world depend 100% on 
largesse from the industry. 
Individual journalists are also 
captured, the committee heard—and 
perhaps most troublesome is the way 
patient organisations have become 
so dependent on the industry. The 
committee concluded that “Measures 
to limit the inﬂ  uence of industry on 
patient groups are needed.” Currently, 
in Britain, we see that the “patients” 
who are trying to convince the British 
government that it should ignore the 
advice of the London-based National 
Institute of Health and Clinical 
Excellence (NICE) (which says that 
drugs for Alzheimer’s disease are not 
sufﬁ  ciently cost effective) are in many 
ways agents of the companies that 
produce those drugs [6].
The consequences of all of these 
incestuous relationships, says the 
committee, are bad decisions on the 
regulation and prescription of drugs, 
over-reliance on drugs rather than on 
other interventions (such as dietary 
change, exercise, or counselling), 
and the “medicalisation” of life’s 
problems, including baldness, shyness, 
unhappiness, grief, and sexual 
difﬁ  culties.
Recommendations:  “Let the Sun 
Shine In”
The committee came up with 48 
conclusions and recommendations, 
and I have listed some of the highlights 
in Box 2. The committee’s main 
recommendation for the problems it 
Box 2. Recommendations from 
the Health Committee Enquiry: 
Some Highlights
• The process of licensing drugs, and the 
medicines’ regulatory system, should 
both be more transparent.
• There should be an independent 
register of clinical trials.
• Clinical trials should focus on using 
health outcomes that are relevant to 
patients.
• More research should be undertaken 
into the adverse effects of drugs and the 
costs of drug-induced illness.
• The regulator should ensure greater 
restraint in medicines’ promotion.
• Tougher restriction should be placed 
on the prescribing activities of non-
specialists.
• Doctors should be required to declare 
signiﬁ  cant sums or gifts they receive as 
hospitality.
• The sponsorship of the drug industry 
should pass from the Department of 
Health to the Department of Trade and 
Industry—because the secretary of state 
for health cannot serve two masters (the 
public and the industry).
(Information taken from [1])
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identiﬁ  es is transparency: “let the sun 
shine in.” It begins by recommending 
that there be a clinical trials register, 
“maintained by an independent body” 
and containing full information. 
Companies should be required to put 
the information on the register “at 
launch as a condition of the marketing 
licence.” The committee also wants 
regulatory authorities and ethics 
committees (the British equivalent of 
institutional review boards) to help 
with the design of trials to make sure 
that they are answering real questions. 
It didn’t, however, recommend more 
public funding of trials. I believe that 
such funding is necessary in order to 
ensure that trials are addressing the 
most important questions—including 
head-to-head comparisons and trials of 
new drugs against older drugs and non-
drug treatments. Advice to companies 
is unlikely to be effective.
There should be, says the committee, 
limits on the quantity of marketing 
materials, particularly in the ﬁ  rst six 
months after launch, and stricter 
controls on marketing to junior 
doctors, nurses, and pharmacists. 
These proposals don’t seem sufﬁ  ciently 
thought through: it’s hard to imagine 
how the proposals would be enforced, 
and they are patronising to junior 
doctors, nurses, and pharmacists—
many of whom are much better, I 
suspect, at assessing evidence than 
burnt out, ageing, high-prescribing 
general practitioners.
The Health Committee would also 
like to see an independent review of 
the Medicines and Healthcare Products 
Regulatory Agency (London, United 
Kingdom) plus a public inquiry every 
time a drug is withdrawn from the 
market on health grounds. It’s hard 
to see the government implementing 
these recommendations, as inquiries 
are expensive and always create 
difﬁ  culties for government, but 
if bodies like the Medicines and 
Healthcare Products Regulatory Agency 
and NICE are to maintain public 
conﬁ  dence they will have to distance 
themselves from the industry—and 
be seen to do so. Important ﬁ  rst 
steps will be to make public more 
of the information they use to make 
their decisions and to exclude KOLs 
from their committees (which may 
be difﬁ  cult, as KOLs include many 
prominent doctors and professors of 
pharmacology and therapeutics).
Doctors’ organisations, says the 
committee, should produce publicly 
available registers of doctors’ links 
with industry. These registers—and 
this is my recommendation and not 
the committee’s—should also include 
information on monetary amounts. 
Otherwise, it will not be possible 
to separate the KOLs from the vast 
numbers of doctors who receive pens, 
lunches, trips, and other gifts from the 
pharmaceutical industry. I doubt very 
much that doctors’ organisations will 
adopt these recommendations until 
forced to do so. In Britain, it’s more 
embarrassing to ask people about 
money than sex. Plus, doctors might 
come to be seen as the villains rather 
than the good guys.
The committee also wants patients’ 
organisations to declare their 
connections with industry and to 
make clear when ubiquitous “disease 
awareness” campaigns are funded by 
the industry, which is probably very 
common [6]. I agree with this support 
for transparency, and while recognising 
the penury of many patients’ 
organisations, I think they would do 
well to resist the lure of the industry’s 
lucre as much as they can.
Conclusion
In the end, this report will probably 
be less remembered for its 
recommendations—most of which 
will probably be ignored—than for 
having brought the important debate 
over the excessive inﬂ  uence of the 
pharmaceutical industry to a broader 
public. We all stand to beneﬁ  t from the 
reduction of that inﬂ  uence.  
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Doctors might come 
to be seen as the villains 
rather than the good 
guys.